The effects of aromatase and 5 alpha-reductase inhibitors, antiandrogen, and sex steroids on Bidder's organs development and gonadal differentiation in Bufo bufo tadpoles.
Embryos of toads (Bufo bufo) were treated with aromatase (4-OHA) and 5 alpha-reductase (17 beta C) inhibitors, antiandrogen (CPA), estradiol-17 beta, testosterone, and 5 alpha-dihydrotestosterone in order to study the role played by sex steroids in the development and sex differentiation of gonads. Test compounds were administered to tadpoles in water and morphometric and cytometric analyses were carried out on histological sections of the cephalic Bidder's organ (a rudimentary ovary) and of the gonadal region. In Bidder's organs, the number and size of oogonia and oocytes were modified by the treatments. However, the female commitment of the Bidder's organ occurs independently from steroid treatments that lead to an acceleration or slackening of the processes of proliferation and differentiation of oogonia. 4-OHA and androgens caused various degrees of inhibition of ovarian differentiation, with gonads maintaining an undifferentiated condition. Estrogen provoked a shift of the sex ratio towards the female sex, yet slackened gonadal growth. 17 beta C accelerated ovarian differentiation in females while CPA enhanced gonadal differentiation in both sexes by promoting the germ and somatic cell proliferation. We suggest that sex hormones may have a local regulatory role in gonadal differentiation during early developmental stages. Furthermore, the strong tendency of Bidderian germ cells to develop in the oogenetic way regardless of sex genotype and steroid treatments, and the quantitative sex differences found in the control Bidder's organs and gonads, suggest that other factors (such as intracellular mechanisms) may be involved in the initial steps of the process of germ cell differentiation.
Petrini
S
S
Department of Biology, University of Bologna, Italy.
Zaccanti
F
F
D058891:5-alpha Reductase Inhibitors; D000726:Androgen Antagonists; D000735:Androstenedione / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology; D000818:Animals; D002023:Bufo bufo / Q000196:embryology*; D004625:Embryo, Nonmammalian / Q000502:physiology; D004791:Enzyme Inhibitors / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D012739:Gonadal Steroid Hormones / Q000494:pharmacology* / Q000502:physiology; D006066:Gonads / Q000254:growth & development*; D008297:Male; D013739:Testosterone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000494:pharmacology
D058891:5-alpha Reductase Inhibitors; D000726:Androgen Antagonists; D004791:Enzyme Inhibitors; D012739:Gonadal Steroid Hormones; C036805:testosterone formate; D013739:Testosterone; D000735:Androstenedione; C014594:formestane